Literature DB >> 20926137

Hydroxyquinoline based binders: promising ligands for chelatotherapy?

Ana Budimir1, Nicholas Humbert, Mourad Elhabiri, Iwona Osinska, Mladen Biruš, Anne-Marie Albrecht-Gary.   

Abstract

We report here a thorough physico-chemical study of the coordination properties of clioquinol, an oxine-type active neurological drug in Alzheimer's disease, toward biologically relevant divalent metal ions (Cu, Zn, Ni, Co and Mn). Using a fruitful combination of electrospray mass spectrometry, absorption spectrophotometry and potentiometry, we have characterized the mono- and bis-chelated metal ion species. The determination of the stability constants showed a classical thermodynamic behavior along the studied series with the cupric complexes being by far the most stable species. Our data are discussed within the scope of Alzheimer's disease.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926137     DOI: 10.1016/j.jinorgbio.2010.08.014

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  3 in total

1.  Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.

Authors:  Kelly L Summers; Graham P Roseman; George J Sopasis; Glenn L Millhauser; Hugh H Harris; Ingrid J Pickering; Graham N George
Journal:  Inorg Chem       Date:  2020-11-23       Impact factor: 5.165

Review 2.  8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications.

Authors:  Veda Prachayasittikul; Supaluk Prachayasittikul; Somsak Ruchirawat; Virapong Prachayasittikul
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

Review 3.  Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease.

Authors:  Abha Sharma; Vidhu Pachauri; S J S Flora
Journal:  Front Pharmacol       Date:  2018-11-15       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.